BEAM

#1661
Beam Therapeutics Inc. Common Stock
30.30 USD
+0.40%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
30.30
30.30
Intervallo Annuale
15.35
36.44
Variazione giornaliera
+0.40%
Variazione Mensile
+17.90%
Variazione di 6 mesi
+18.08%
Variazione Annuale
+80.57%
Chiusura Precedente
30.18
Apertura
30.30
Bid
Ask
Minimo
30.30
High
30.30
Volume
118
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
  • Market Capitalization 3.09 B
  • Employee 511
  • Founded 2017
  • CEO John Evans
  • Website www.beamtx.com
  • Headquarter Delaware, United States
  • FIGI BBG00KXC8646
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-34.22
Rapporto prezzo/fatturato
19.62

Beam Therapeutics Inc

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Notizie